The role of genetic variants in DBS outcomes was also addressed by a recent study in which 85 PD patients who were treated with STN-DBS were examined for SNCA rs356219 and rs356220 polymorphisms in the 3’ untranslated region of the gene. The gene discussed is SNCA; the disease is Parkinson disease.